Ironvine Capital Partners LLC Sells 4,916 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ironvine Capital Partners LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,789 shares of the medical research company's stock after selling 4,916 shares during the quarter. Thermo Fisher Scientific comprises 4.1% of Ironvine Capital Partners LLC's portfolio, making the stock its 11th largest position. Ironvine Capital Partners LLC's holdings in Thermo Fisher Scientific were worth $37,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Barrett & Company Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $30,000. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Evercore ISI lowered their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday. Royal Bank of Canada dropped their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday. Robert W. Baird cut their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday. Finally, Raymond James restated an "outperform" rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $616.95.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $6.34 during trading on Monday, hitting $417.90. The company had a trading volume of 1,047,838 shares, compared to its average volume of 1,740,959. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market capitalization of $157.76 billion, a P/E ratio of 25.28, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The stock has a 50 day simple moving average of $487.28 and a 200 day simple moving average of $526.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.11 earnings per share. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. The trade was a 7.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 over the last 90 days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.